Oral IL-17 Inhibitor, Psoriasis
IL-17 is implicated in multiple inflammatory and autoimmune diseases and is the subject of numerous clinical studies. The first significant market to be targeted by anti-IL-17 therapies is psoriasis, which is estimated to be worth $9bn per annum with Cosentyx® (Novartis) being approved in Jan 2015. Other significant IL-17 market opportunities include psoriatic arthritis and ankylosing spondylitis, together estimated to be worth a further $6bn per annum.
Current attempts to target IL-17 are largely based around monoclonal antibodies, which have the necessary size required to inhibit the IL-17/IL-17R engagement. Historically, identifying small molecules that specifically inhibit the IL-17 pathway has been extremely challenging, but our technology has enabled identification of small molecules that can selectively block the IL-17/IL-17R interaction. These are more conventional, drug-like compounds, for oral and/or topical use, which would offer benefits over injectable therapies such as IL-17 antibodies.